title: Clinical trials in systemic lupus erythematosus: a status report on ongoing trials.
abstract: To describe the characteristics of trials in systemic lupus erythematous (SLE) listed in ClinicalTrials.gov such as study design, funding sources and aspects of the disease and drugs under investigation. We conducted a survey of ongoing clinical trials that were registered in the ClinicalTrials.gov website. We used the advanced search option and applied the following inclusion criteria, "SLE," "open studies," "interventional," and "adults 18 years or older." Of 97 eligible studies, 34.0 % were phase 3 or 4, 49.5 % were phase 1, 2 or 2/3 and in 16.5 %, we could not determine the study phase. Most trials were randomized (69.0 %) and 48.4 % were double blinded; 34 % of the trials were placebo controlled, 19.6 % had an active agent comparator and 46.4 % had no comparator. Universities and pharmaceutical industries were the primary sponsors for 45.3 and 39.1 % of the trials, respectively, and government agencies for 10.3 %. Multi-center trials based in the USA (US) accounted for 40.2 % of the trials, 46.4 % were outside of the US and 13.4 % were in the US as well as other countries. The most frequently used endpoint was drug efficacy (30.9 %) followed by disease severity indices (25.7 %), drug safety (14.4 %), remission rates and times to remission (7.2 %), and inflammatory markers and antibody titers (7.2 %). The majority of ongoing clinical trials in SLE are university or industry-funded, randomized phase 1, 2, or 2/3 trials, focused on drug efficacy. Federal funding for trials in SLE within and outside the US remains low.
authors.affiliation: St. Louis University School of Medicine, St. Louis, MO, USA.
authors.forename: Divya
authors.initials: D
authors.lastname: Gumber
authors.forename: Jisna
authors.initials: J
authors.lastname: Paul
authors.forename: Prabha
authors.initials: P
authors.lastname: Ranganathan
mesh_terms: D002986:Clinical Trials as Topic / Q000191:economics / Q000379:methods*; D019538:Health Care Surveys; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000628:therapy*; D012042:Registries; D012107:Research Design; D012109:Research Support as Topic; D016896:Treatment Outcome
references.citation: Stud Health Technol Inform. 2004;107(Pt 2):1466-70
references.pmid: 15361058
references.citation: Arthritis Rheum. 2009 Sep 15;61(9):1168-78
references.pmid: 19714604
references.citation: Lupus. 2000;9(5):322-7
references.pmid: 10878722
references.citation: J Allergy Clin Immunol. 2011 Feb;127(2):303-12; quiz 313-4
references.pmid: 21281862
references.citation: Isr Med Assoc J. 2002 Jan;4(1):71-3
references.pmid: 11802320
references.citation: JAMA. 2003 Mar 5;289(9):1107-16
references.pmid: 12622580
references.citation: Best Pract Res Clin Rheumatol. 2002 Apr;16(2):313-32
references.pmid: 12041956
references.citation: Lancet. 2002 Apr 13;359(9314):1337-40
references.pmid: 11965296
references.citation: Expert Opin Biol Ther. 2014 Apr;14(4):491-501
references.pmid: 24490627
references.citation: J Clin Epidemiol. 2010 Aug;63(8):834-40
references.pmid: 20346629
references.citation: JAMA. 2004 Sep 15;292(11):1363-4
references.pmid: 15355936
references.citation: Trends Mol Med. 2010 Feb;16(2):47-57
references.pmid: 20138006
references.citation: Best Pract Res Clin Rheumatol. 2005 Oct;19(5):859-78
references.pmid: 16150407
references.citation: Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
references.pmid: 12604793
references.citation: Rheumatol Int. 2012 Jun;32(6):1831-5
references.pmid: 21769487
references.citation: Nat Rev Rheumatol. 2014 Jan;10(1):23-34
references.pmid: 24100460
references.citation: JAMA. 2012 May 2;307(17):1838-47
references.pmid: 22550198
references.citation: Biologics. 2010 Sep 13;4:263-71
references.pmid: 20859453
references.citation: BMJ. 2003 May 31;326(7400):1167-70
references.pmid: 12775614
references.citation: J Clin Invest. 2003 Jul;112(2):286-97
references.pmid: 12865416
references.citation: JAMA. 2006 Feb 1;295(5):527-35
references.pmid: 16449618
references.citation: Curr Opin Rheumatol. 2006 Sep;18(5):476-80
references.pmid: 16896285